Bruker a new Sector Perform at RBC as gains 'appear in the rearview'
RBC Capital Markets initiated coverage on Bruker (BRKR) with a Sector Perform rating, suggesting that the life sciences scientific instruments maker's opportunities for significant gains are now limited. Analyst Dan Leonard cited Bruker's innovation but balanced it against an over-reliance on semiconductor capital equipment for future outperformance and exposure to markets mismatched with current growth trends. Bruker shares were down approximately 7% following the announcement.
People in the News at Bruker, nRichDx, Belay Diagnostics
Bruker, nRichDx, and Belay Diagnostics have announced new appointments to their respective teams. The article, published on November 16, 2026, details the latest personnel changes at these companies in the news section of GenomeWeb.
Bruker Appoints Biopharma Entrepreneur and Immunology Leader Eicke Latz to Board
Bruker Corporation has appointed Dr. Eicke Latz, a physician-scientist and biopharma entrepreneur specializing in immunology, to its Board of Directors, effective January 1, 2027. Dr. Latz brings extensive experience in academic research, biotechnology company formation, and drug development, particularly in innate immunity and inflammation. His appointment aims to enhance Bruker's expertise in disease biology and biopharmaceutical development as the company expands its life sciences and drug discovery technologies.
Bruker adds biotech entrepreneur Eicke Latz to board
Bruker Corporation announced the appointment of Eicke Latz, MD PhD, to its Board of Directors, effective January 1, 2027. Dr. Latz is a distinguished medical institute director and physician-scientist known for co-founding five biotechnology companies and his expertise in innate immunity and inflammation research. His addition is expected to bring valuable disease biology leadership and biopharma entrepreneurial experience as Bruker expands its life-science tools business.
Should You Continue to Retain Bruker Stock in Your Portfolio?
Bruker Corporation (BRKR) is positioned for growth due to strong performance in its Biosystems and Diagnostics businesses, preclinical imaging expansion, and progress toward a $140 million cost-savings target. Despite these positives, uneven academic demand and macroeconomic uncertainties pose ongoing concerns for the company. The stock has outperformed the S&P 500 Composite over the past year, and analysts remain optimistic about its future earnings.
Is Bruker (BRKR) A Bargain Following Reaffirmed Outlook And Mixed Q3 Results?
Bruker (BRKR) recently released mixed Q3 2026 results, including higher sales but also a larger goodwill impairment charge and a wider loss, while reaffirming its full-year outlook. Despite a recent share price decline, the stock has shown positive momentum over the past month and year-to-date. Analysts currently view Bruker as slightly undervalued, with a fair value of approximately $63.83.
Bruker Corporation $BRKR Stock Sold by M&G PLC
M&G PLC significantly reduced its stake in Bruker Corporation, selling 62.2% of its holdings in the third quarter but retaining 425,645 shares valued at $27.7 million. Despite the institutional selling, Bruker reported strong quarterly earnings of $0.56 EPS on revenue of $874 million, both exceeding analyst estimates. The stock, which has a "Moderate Buy" consensus rating from analysts, was up 8.5% and opened at $66.54.
Bruker (NASDAQ:BRKR) Price Target Raised to $64.00
Citigroup analysts have increased their price target for Bruker (NASDAQ:BRKR) to $64.00 from $53.00, maintaining a "hold" rating, suggesting a potential upside of 4.39%. This update comes alongside other analyst adjustments, resulting in an average "Moderate Buy" rating and a $60.57 price target for the company. Bruker recently reported strong quarterly earnings, beating analyst estimates with $0.56 EPS on revenues of $874.00 million.
Form 10-Q BRUKER CORP For: Sep 30
This article announces that Bruker Corp. has filed its Form 10-Q for the period ending September 30. The filing was made on November 5, 2026, and provides financial details for the company. The document is accessible via an archive link.
Bruker Corporation stock hits 52-week high at 66.99 USD
Bruker Corporation (BRKR) stock has reached a new 52-week high of $66.99, currently trading at $67.24, reflecting a significant 1-year return of 40.51% and a 6-month surge of 55.52%. Despite concerns about the company being overvalued by InvestingPro's Fair Value analysis, analysts have set price targets ranging from $50 to $80. Recent financial reports indicate an earnings beat but a revenue miss for Q2 2026, alongside a declared quarterly cash dividend of $0.05 per share, with Stifel raising its price target to $50.
Bruker Reports 2 Percent Q3 Revenue Rises, Lowers 2026 Guidance
Bruker reported a 2 percent increase in its third-quarter revenue but also announced a reduction in its revenue guidance for 2026. This financial update indicates mixed results for the company, with growth in the recent quarter but a more conservative outlook for future performance.
Bruker Corporation Common Stock (BRKR) Financial Statements
This article provides key financial statistics and trading information for Bruker Corporation Common Stock (BRKR). It highlights the company's market capitalization, trading volume, dividend yield, and its 52-week high and low prices. The content also guides users on how to track, buy, and sell BRKR shares on the Pluang platform, emphasizing its regulation by the OJK.
Bruker Corporation (BRKR) Stock forecasts
Argus has raised its target price for Bruker Corporation (BRKR) to $64.00. Bruker Corp is a manufacturer of scientific instruments and diagnostic tests for various industries including life sciences, applied markets, pharmaceutical, and biotechnology. The stock's current price is $57.07.
Press Release: Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
Bruker Corporation announced it will release its third-quarter 2026 earnings after the market closes on Thursday, October 30, 2026. The company will host a conference call and webcast on the same day at 5:00 PM ET to discuss its financial results and business outlook.
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
Bruker Corporation announced it will report its third-quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss these results and current business trends. Investors can access the webcast and pre-register for the conference call through Bruker's investor relations website.
J.P. Morgan Downgrades Bruker Corp(BRKR.US) to Hold Rating, Maintains Target Price $60
J.P. Morgan has downgraded Bruker Corp (BRKR.US) from an Overweight to a Hold rating. The firm has opted to maintain its target price for the company at $60.
Bruker Corp (BRKR) Shares Fall 4.4% -- What GF Score of 83 Tells Investors
Bruker Corp (BRKR) shares recently fell 4.4% to $56.25, placing it at a 6.9% undervaluation compared to its GF Value™ of $60.43. Despite a "Strong" GF Score™ of 83/100, indicating good overall performance with strong momentum and reasonable valuation, the company faces concerns due to its unprofitability, negative cash flow, and $3.6M in insider selling over the past year. Investors are advised to weigh these conflicting signals carefully, considering both the guru interest and the company's financial vulnerabilities.
Bruker Gains 66.3% in a Year: What's Driving the Rally?
Bruker Corporation (BRKR) has seen its shares rise 66.3% over the past year, driven by strong demand in biopharma, security detection, molecular diagnostics, and mass spectrometry, as well as growth in its preclinical imaging portfolio. Despite a significant non-cash goodwill impairment in Q2 2026 and sensitivity to exchange-rate changes, the company maintains healthy fundamentals and solid growth opportunities. Analysts' consensus estimate for 2026 EPS remains unchanged at $2.12, with an estimated long-term EPS growth rate of 15.4%.
Bruker Gains 66.3% in a Year: What's Driving the Rally?
Bruker Corporation has seen its shares rise by 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry, with significant revenue growth in its CALID businesses. Despite facing challenges like a $134.9 million goodwill impairment and currency pressures, the company's solid solvency and preclinical imaging portfolio contribute to its positive outlook. Analysts predict full-year 2026 revenues between $3.54 billion and $3.57 billion.
A blood study found 179,049 different forms of human proteins
Bruker Corporation (BRKR) announced a research preprint detailing a draft atlas of human plasma protein variants, or proteoforms, mapped using its timsTOF systems. The study, led by Markus Ralser at Charité – Universitätsmedizin Berlin, identified 5,077 plasma protein groups across 179,049 distinct proteoforms, revealing a vast molecular landscape for biomedical research. This breakthrough aims to advance understanding of physiology, disease mechanisms, and biomarker discovery by focusing on the molecular isoforms that carry biological function.
Bruker Corporation (BRKR) stock price, news, quote and history
This article provides a comprehensive overview of Bruker Corporation (BRKR), including its current stock price, financial performance metrics, and analyst ratings. It details the company's business segments in scientific instruments and analytical solutions, along with key financial data such as market capitalization, earnings per share, and revenue. The article also includes historical performance data, earnings trends, and a comparison with the S&P 500 benchmark.
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Bruker Corporation announced new timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026. These advancements aim to enhance protein-sequence coverage, targeted validation, glycopeptide characterization, structural proteomics, and oligonucleotide analysis. The new workflows facilitate deeper understanding of proteoforms, protein interactions, and nucleic acids, contributing to drug discovery, disease biology research, and the development of next-generation biological AI models.
Arm leads Wednesday's losers with an 8.5% drop as Bruker tops the gainers
On Wednesday, September 24, Arm experienced the steepest decline among 111 priority stocks, dropping 8.5%, while Bruker led the gainers with a 7.5% increase. Other notable movers included Tempus AI and IonQ on the upside, and Digital Turbine, GoPro, General Motors, and SanDisk among the decliners. The article also touches upon Meta's significant positive close and the spread of gains and losses across various sectors.
UC Berkeley orders more than $6 million in research equipment from Bruker
Bruker Corporation announced a multi-system order exceeding $6 million from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation. This investment, expected to be delivered in 2027, will significantly upgrade the Pines Magnetic Resonance Center, enhancing research capabilities in various scientific fields. The new equipment, including an AV NEO-X 800 MHz spectrometer, aims to propel UC Berkeley to the forefront of innovation in magnetic resonance.
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
Bruker Corporation announced a multi-system order from the University of California, Berkeley, for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. This investment, exceeding $6 million, will enhance UC Berkeley's research capabilities in chemistry, materials science, structural biology, and related fields by integrating next-generation NMR technologies, including an 800 MHz AV NEO-X spectrometer and MAS CryoProbe. The new systems are expected to be delivered in 2027, bolstering the center's ability to conduct multidisciplinary studies on molecular structure and dynamics.
Bruker (BRKR) EVP sells 2,000 shares under trading plan
Mark Munch, EVP and President of Bruker Nano Inc., an executive at Bruker Corp (BRKR), exercised stock options for 2,000 shares and subsequently sold all of them on September 15, 2026. The transaction was conducted under a Rule 10b5-1 trading plan. He exercised the options at $22.19 per share and sold the shares at $52.87 per share, resulting in an approximate pre-tax spread of $61,000.
Bruker (NASDAQ: BRKR) officer to sell 2,000 shares
Bruker Corporation officer Mark R. Munch has filed a Rule 144 notice to sell 2,000 shares of BRKR common stock, valued at approximately $105,740. This planned sale follows similar recent sales by Munch of 2,000 shares each in July and August 2026. The shares to be sold originated from a stock option exercise, and the transaction will be executed through Morgan Stanley Smith Barney on NASDAQ.
Bruker at Wells Fargo Healthcare Conference: deep tech drives growth
Bruker Corporation outlined its business strategy at the Wells Fargo Healthcare Conference, highlighting strong demand in "deep tech" sectors like semiconductor metrology, defense, and fusion research, which are driving growth despite longer delivery cycles. The company also detailed its strategic shifts in life sciences, including the integration of AI and acquisitions like Mimetas, and discussed promising opportunities in proteomics. While facing near-term headwinds from AI infrastructure spending in life sciences, Bruker remains confident in future growth driven by innovation and strategic market positioning.
Bruker Corp (BRKR) Shares Fall 4.3% -- What GF Score of 84 Tells Investors
Bruker Corp (BRKR) shares dropped 4.3% to $56.98, yet its GF Score of 84/100 indicates strong overall performance. The stock is considered slightly undervalued with a GF Value of $60.24, despite unprofitability and recent insider selling worth $3.6 million. Investors are advised to exercise caution and conduct further evaluation due to these mixed signals.
Barclays Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $58
Barclays has reiterated its Buy rating for Bruker Corp (BRKR.US) but has adjusted its price target downwards to $58. This indicates a continued positive outlook on the company's stock despite a revision in its valuation.
Bruker Corp (XTER:BKD) Stock Price & 30 Year Financial Data
This article provides 30-year financial data for Bruker Corp (XTER:BKD), including key growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, and book value. It details the company's current stock price, market capitalization, and various financial ratios. The page also outlines how GuruFocus calculates growth rates and presents options for viewing and exporting financial data.
Ceredex Value Advisors LLC Acquires Shares of 213,450 Bruker Corporation $BRKR
Ceredex Value Advisors LLC has acquired 213,450 shares of Bruker Corporation (NASDAQ:BRKR) valued at approximately $12.8 million. Other institutional investors also adjusted their positions, with hedge funds and institutional investors collectively owning 79.52% of the company. Bruker reported an EPS of $0.49, surpassing estimates, and declared a quarterly dividend of $0.05 per share, while analysts maintain a "Moderate Buy" rating with a target price of $56.64.
Advisors Capital Management LLC Purchases Shares of 81,937 Bruker Corporation $BRKR
Advisors Capital Management LLC has acquired a new position in Bruker Corporation, purchasing 81,937 shares valued at approximately $4.93 million. This makes them owners of about 0.05% of Bruker's stock. Other institutional investors have also adjusted their holdings, with significant increases from Orbis Allan Gray Ltd, Pallas Capital Advisors LLC, State Street Corp, AQR Capital Management LLC, and Sculptor Capital LP.
Bruker Corporation (NASDAQ:BRKR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Bruker Corporation (NASDAQ:BRKR) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $56.64. The company recently exceeded earnings expectations with $0.49 EPS against a $0.38 consensus but fell short on revenue estimates, reporting $838.5 million. Several firms have adjusted their price targets, and Bruker also declared a quarterly dividend of $0.05 per share.
Trending Industry Today: Bruker Corp Leads Gains In Room-Temp Superconductors Stocks
The article discusses the trending industry of room-temperature superconductors, highlighting Bruker Corp as a leading gainer in this sector.
Old West Investment Management LLC Acquires Shares of 667,103 Bruker Corporation $BRKR
Old West Investment Management LLC has acquired a significant new stake of 667,103 shares in Bruker Corporation (NASDAQ:BRKR), valued at approximately $40.1 million. This makes Bruker its largest portfolio holding, representing 4.3% of its assets and about 0.44% of Bruker's total shares. Bruker recently reported strong quarterly earnings, beating EPS estimates, though revenue slightly missed expectations, while analysts hold a "Moderate Buy" consensus rating for the stock.
Bruker declares $0.05 quarterly dividend for common shareholders
Bruker Corporation (NASDAQ:BRKR) has declared a quarterly cash dividend of $0.05 per share, payable on October 7, 2026. This dividend results in a 0.35% yield and comes as the stock has seen a 73% gain over the past year. Despite strong shareholder yield, the stock is considered overvalued according to InvestingPro analysis, and the company recently surpassed profit expectations while revenue fell short.
Bruker Corp Executive Mark Munch Reports Share Withholding to Cover RSU Tax Obligations
Mark Munch, Executive Vice President and President of Bruker Nano Inc., disposed of 1,619 shares of Bruker Corp common stock on August 11, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units. The shares, valued at $57.02 each, were withheld by the company. After this transaction, Munch directly owns 123,347 shares of Bruker Corp.
Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
Bruker Corporation announced an expanded strategic collaboration with Atinary Technologies Inc., a pioneer in Self-Driving Labs technologies and AI-driven R&D, which also includes a minority investment by Bruker. The collaboration aims to integrate Atinary's SDLabs platform with Chemspeed automation and Bruker instruments to create closed-loop, AI-driven R&D workflows for accelerated scientific discovery. This initiative will enable scientists to use AI agents for designing experiments, navigating molecular spaces, and interpreting results, thereby accelerating the development of new molecules and materials.
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
J.P. Morgan has reiterated its Buy rating on Bruker Corp (BRKR.US) but has revised its target price downwards to $60. This adjustment reflects J.P. Morgan's updated valuation for the company while maintaining a positive outlook on its stock.
Bruker takes majority stake in organ-on-a-chip firm MIMETAS
Bruker Corporation has acquired a majority stake in MIMETAS B.V., a company specializing in organ-on-a-chip platforms and human tissue models for drug discovery. This investment will allow Bruker to integrate MIMETAS' OrganoPlate platform with its existing technologies, expanding its offerings in Microphysiological Systems. MIMETAS will continue to operate under its current brand and management.
MIMETAS Receives Majority Investment From Bruker Corporation
MIMETAS B.V., a Netherlands-based provider of organ-on-a-chip platforms, has secured a majority investment from Bruker Corporation to scale its operations and expand the global availability of its human tissue models. The investment will also facilitate the development of integrated product and service workflows connecting MIMETAS's systems with Bruker's technologies. MIMETAS develops scalable platforms and human tissue models used by pharmaceutical and biotechnology companies for drug discovery and disease mechanism studies.
Leiden research group sees spin-off grow into a success story
Mimetas, a spin-off from Thomas Hankemeier’s research group at Leiden University, is being acquired by Bruker Corporation, marking a significant success in organ-on-a-chip technology. The acquisition highlights how scientific innovation from a university lab can evolve into an internationally leading company, demonstrating the societal impact of academic research in drug discovery and development. Hankemeier emphasizes the importance of entrepreneurial spirit and sees further opportunities for collaboration and growth within the Leiden and Dutch innovation ecosystem.
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue models. This investment aims to expand Bruker's post-genomic solutions for disease biology research and drug discovery into Microphysiological Systems (MPS). The collaboration will combine MIMETAS's OrganoPlate® platform with Bruker's technologies to offer integrated workflows for disease research, compound evaluation, and drug development.
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
J.P. Morgan has reiterated its "Buy" rating on Bruker Corp (BRKR.US) but has lowered the price target for the stock to $60. This adjustment reflects a revised outlook from the analyst firm while maintaining a positive investment stance on the company.
Amundi Increases Stock Position in Bruker Corporation $BRKR
Amundi increased its stake in Bruker Corporation (NASDAQ:BRKR) by 244.2% in the first quarter, now holding 62,611 shares valued at $2.26 million. Despite the company beating EPS estimates for Q2 2026 with $0.49 per share, its revenue of $838.5 million missed analyst expectations, raising concerns about demand and growth in its primary market. Analysts maintain a "Moderate Buy" consensus rating with a target price of $56.64, though some have lowered their targets due to revenue performance.
Bruker Corp (BRKR): FMR LLC and Abigail Johnson report 15% ownership
FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Bruker Corp (BRKR) common stock, as detailed in a Schedule 13G/A SEC filing. FMR LLC beneficially owns 23,296,465.55 shares, with sole voting power over 17,974,598.38 shares and sole dispositive power over all its shares. Abigail P. Johnson is also listed with beneficial ownership of 23,296,465.55 shares, holding sole dispositive power.
Bruker Corp (BRKR) Stock Up 4.3% and Still Undervalued -- GF Sco
Bruker Corp (BRKR) shares rose 4.3% to $52.47, trading below its GF Value™ of $62.94, suggesting it is undervalued despite being currently unprofitable and cash-flow negative. The company has a strong GF Score™ of 85/100, driven by good profitability and momentum, though its financial strength is moderate. While gurus are largely increasing their positions, insider selling raises some cautious signals for investors.
Citi Maintains Bruker Corp(BRKR.US) With Hold Rating, Cuts Target Price to $53
Citi has reiterated its Hold rating on Bruker Corp (BRKR.US) while simultaneously lowering its target price for the company's stock to $53. This adjustment reflects Citi's updated outlook for Bruker Corp.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $70
Guggenheim has reiterated its Buy rating for Bruker Corp (BRKR.US), maintaining a target price of $70. This indicates a continued positive outlook from the firm regarding Bruker's stock performance and value.